SOAT1 and colorectal carcinoma: As mentioned earlier, ZNFs affect the signaling pathway activities such as WNT, JAK‐STAT, etc. Therefore, the development and use of inhibitors of WNT and JAK‐STAT signaling pathways will probably also be effective clinical agents for the treatment of CRC patients with altered ZNF abundance.